DR. RAVI RAO
(MBBS, FRACS, IFASMBS) Minimal Invasive Surgeon , Advanced Laparoscopy & Bariatrics
Buy Ivermectin for humans Australia, Ivermectin over the counter Australia
Ivermectin Products for Animals Are Different from Ivermectin Products for People. WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. The group reviewed pooled data from 16 randomized controlled trials (total enrolled 2407), that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. They determined that the evidence on whether ivermectin reduces mortality and safe only when used in animals as prescribed.
Ivermectin in COVID-19.
These pages contain the scientific rationale that justifies the use of ivermectin in COVID-19. In March 2020 we created our life-saving MATH+ Hospital Treatment Protocol for COVID-19, in the American Journal of Therapeutics! Dr. Yu has refused the ivermectin requests, he said, ivermectin is more commonly used in animals. Physicians are raising alarms about a growing number of people getting the drug from livestock supply centers, approved for treating or preventing Covid-19 and that taking large doses can cause serious harm. Researchers and physicians are particularly alarmed by people seeking out ivermectin as a form of possible prevention or treatment instead of getting one of the highly effective Covid vaccines.
Ivermectin for treating or preventing COVID-19 infection
We wanted to know if ivermectin reduces death, illness, and length of infection in people with COVID-19 and there are 18 studies still requiring clarification from the authors or not yet published. We don't know whether ivermectin compared with placebo or usual care, inhibits the replication of viruses in vitro. The molecular hypothesis of ivermectin's antiviral mode of action suggests an inhibitory effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in the early stages of infection. Ivermectin compared to placebo or standard of care for inpatient COVID-19 treatment. Ivermectin medicines are not authorised for use in COVID-19 in the EU, in light of the ongoing discussions on the use of ivermectin in the prevention and treatment of COVID-19.
New restrictions on prescribing ivermectin for COVID-19.
There is only one TGA approved oral ivermectin product, Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV-2.
This EMA public health statement has been endorsed by the COVID-19 EMA pandemic Task Force (COVID-ETF), in light of the ongoing discussions on the use of ivermectin in the prevention and treatment of COVID-19. 1 Czechia and Slovakia, have allowed the temporary use of the medicine for COVID-19 within the remit of their national legislation. 1. Elgazzar, A., et al., Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Research Square, 2020. 2. Ahmed, S., et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis, 2021. 103: p. 214-216. 3. Alam, M.T., et al., Ivermectin as pre-exposure prophylaxis for COVID-19 among healthcare providers in a selected tertiary hospital in Dhaka – an observational study. European Journal of Medical Health and Sciences, 2020. 4. Arévalo, A.P., et al., Ivermectin reduces coronavirus infection in vivo: a mouse experimental model. Biorxiv, 2020. 5. Babalola, O.E., et al., Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double-blind, dose-response study in Lagos. QJM, 2021. 6. Behera, P., et al., Prophylactic role of ivermectin in SARS-CoV-2 infection among healthcare workers. Research Square, 2021. 7. Bray, M., et al., Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral Res, 2020. 178: p. 104805. 8. Caly, L., et al., The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res, 2020. 178: p. 104787. 9. Camprubí, D., et al., Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One, 2020. 15(11): p. e0242184. 10. Carvallo, H., et al., Safety and efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID 19. MedRxiv, 2020. 11. Carvallo, H., et al., Study of the efficacy and safety of topical ivermectin + iota-carrageenan in the prophylaxis against COVID-19 in health personnel. Journal of Biomedical Research and Clinical Investigation, 2020. 12. Castañeda-Sabogal, A., et al., Outcomes of ivermectin in the treatment of COVID-19: a systematic review and meta-analysis. Medrxiv, 2021. 13. Chaccour, C., et al., Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. Sci Rep, 2020. 10(1): p. 17073. 14. Chaccour, C., et al., The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine, 2021: p. 100720. 15. Chachar, A.Z.K., et al., Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients. International Journal of Sciences, 2020. 9(09): p. 31-35. 16. Chowdhury, A.T.M.M., et al., A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients. Research Square, 2020. 17. de Melo, G.D., et al., Anti-COVID-19 efficacy of ivermectin in the golden hamster. BioRxiv, 2020. 18. Elalfy, H., et al., Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID ‐ 19. J Med Virol, 2021. 19. Errecalde, J., et al., Safety and pharmacokinetic assessments of a novel ivermectin nasal spray formulation in a pig model. J Pharm Sci, 2021. 20. Espitia-Hern, G., et al., Effects of ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study. Biomedical Research, 2020. 21. Formiga, F.R., et al., Ivermectin: an award-winning drug with expected antiviral activity against COVID-19. J Control Release, 2020. 22. Gonzalez, J.L.B., et al., Efficacy and safety of ivermectin and hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial. Medrxiv, 2021. 23. Gorial, F.I., et al., Effectiveness of ivermectin as add-on therapy in COVID-19 management (pilot trial). Medrxiv, 2020. 24. Hashim, H.A., et al., Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. Medrxiv, 2020. 25. Hellwig, M.D., and Maia, A., A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. Int J Antimicrob Agents, 2021. 57(1): p. 106248. 26. Hill, A., et al., Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Research Square, 2021. 27. Jermain, B., et al., Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 drug repurposing. J Pharm Sci, 2020. 109(12): p. 3574-3578. 28. Kalfas, S., et al., The therapeutic potential of ivermectin for covid-19: a systematic review of mechanisms and evidence. Medrxiv, 2020. 29. Khan, M.S.I., et al., Ivermectin treatment may improve the prognosis of patients with COVID-19. Arch Bronconeumol, 2020. 56(12): p. 828-830. 30. Kim, M.S., et al., Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis. PLoS Med, 2020. 17(12): p. e1003501. 31. Kory, P., et al., Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. FlCCC.net, 2021. 32. Krolewiecki, A., Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial. Lancet preprint, 2020. 33. Lehrer, S., and Rheinstein, P.H., Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In Vivo, 2020. 34(5): p. 3023-3026. 34. Lima-Morales, R., et al., Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. Int J Infect Dis, 2021. 35. López-Medina, E., et al., Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA, 2021. 36. Mittal, N. and Mittal, R., Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19? Med Hypotheses, 2021. 146: p. 110364. 37. Mohan, A., et al., Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial. Research Square, 2021. 38. Niaee, M.S., Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial. Research Square, 2020. 39. Okumuş, N., et al., Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 Patients. Research Square, 2021. 40. Patel, A., Desai, S., et al, RETRACTED, Ivermectin in COVID-19 related critical illness. 2020. 41. Podder, C.S., et al., Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. IMC J Med Sci, 2020. 42. Rajter, J.C., et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in covid nineteen study. Chest, 2021. 159(1): p. 85-92. 43. Ravikirti, R., et al., Ivermectin as a potential treatment for mild to moderate COVID-19 – a double blind randomized placebo-controlled trial. Medrxiv, 2021. 44. Bukhari, S.K.H.S., et al., Efficacy of ivermectin in COVID-19 patients with mild to moderate disease. Medrxiv, 2021. 45. Soto-Becerra, P., et al., Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru. Medrxiv, 2020. 46. Spoorthi, V., and Surapaneni, S., Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV-2. International Archives of Integrated Medicine, 2020.
Dr. Ravi Rao has been awarded “Surgeon of Excellence” for 2017-2020 by Surgical review corporation, USA. Dr. Rao has received the recognition for demonstrating an unparalleled commitment and ability to consistently deliver safe, effective, evidence-based care.
AWARDS AND RECOGNITION
Surgeon of Excellence (SOE)
commendation for safe and high-quality surgical care, Dr. Ravi has demonstrated that he meets the requirements for delivery of high-quality perioperative and long term follow-up care for his patients.
Laparoscopic Transcystic Common Bile Duct Exploration
Rao RS, Webber L, Fletcher D, Ballal M. at 81st Annual Scientific Congress, RACS
Endoscopic Total Thyroidectomy
Rao RS, Duncan TD In JSLS / PMID: 20202393
Botulinum toxin for treatment of non-neurogenic bladders in children – a case series
Rao RS, Barker AB In BJU International. Vol. 97 Issue S1 Page 23-23
Management of Blunt Abdominal Trauma
A prospective 2year Study between 1995-1997, A Dissertation In Partial fulfillment for the Award of Diplomate of National Board, General Surgery, accepted by The National Board of Examinations
Botulinum toxin for treatment of non-neurogenic bladders in children – a case series
At Royal Australasian College of Urology Conference
Botox and Paediatric Incontinence
At International conference of Paediatric Surgeons
Epidemiology of Vascular Trauma
In Western Australia – 10 year study
Comparison Between Onlay and Inlay Mesh Repair
At IASA conference State Chapter
At Association of Surgeons India
Management of pleomorphic adenomas – superficial parotidectomies
A Case Series, AWARD PAPER , Indian Association Of Surgeons Conference
At Appendicectomy – Laparoscopic or open
At Continuing Medical education, National Surgical conference, KIMS
Suchitra Rao, Practice Manager
Stevie Raymond, Dietitian
Dr Paul Young,
Dr. Paul Cosentino,
Dr. Edward Velzeboer,